Like adults with high cholesterol or high blood pressure, people with depression are at increased risk of cardiovascular disease (CVD) events, such as heart attacks and strokes. The aim of this clinical trial is to reduce the CVD risk of people with depression by comparing a control group receiving current primary care for depression to an intervention group receiving an updated version of collaborative care for depression called eIMPACT. 216 patients with depression and CVD risk factors are being recruited from the primary care clinics of Eskenazi Health, a safety net healthcare system in Indianapolis. The primary outcome is endothelial dysfunction (ultrasound). The secondary outcomes are autonomic dysfunction (ECG), inflammation and platelet activation biomarkers (blood draw), and depressive symptoms (self-report).
This trial could identify a novel target (depression) for CVD primary prevention efforts and equip healthcare providers with a new tool (eIMPACT) to manage the CVD risk of their patients. It is our long-term hope that treating depression in primary care will reduce the disability and death caused by CVD.
This is a 5-year study funded by the National Heart, Lung, and Blood Institute.
Due to the success of HIV mediations (highly effective antiretroviral therapy), people with HIV are living longer, and HIV is now considered to be a chronic disease. Unfortunately, people with HIV have an increased risk of multiple chronic diseases, including cardiovascular disease (CVD). The causes of this elevated CVD risk are not fully understood.
The aim of this clinical trial is to determine whether treating depression with an online cognitive-behavioral treatment program called Beating the Blues© lowers the CVD risk of people with HIV. 110 patients with treated HIV and depression are being recruited from HIV clinics in Indianapolis. The primary outcome is endothelial dysfunction (ultrasound), and the secondary outcomes are inflammation and coagulation biomarkers (blood draw). Results of this trial will help to determine the relationships of depression and its treatment with inflammation, coagulation, and endothelial dysfunction. Ultimately, this line of research could provide clinicians with a novel and easily implementable tool (Beating the Blues©) to prevent CVD morbidity and mortality in their patients with HIV.
This is a 4-year study funded by the National Heart, Lung, and Blood Institute.